Nkarta (NKTX) Revenue & Revenue Breakdown
Nkarta Revenue Highlights
00
Nkarta Revenue by Period
Nkarta Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | -100.00% |
2019-12-31 | $115.39K | -98.24% |
2018-12-31 | $6.55M | - |
Nkarta Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $10.54M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $385.00 | -200.00% |
2019-09-30 | $-385.00 | -116.68% |
2019-06-30 | $2.31K | -97.96% |
2019-03-31 | $113.08K | - |
Nkarta Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ALEC | Alector | $97.06M | $15.08M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
KZR | Kezar Life Sciences | $7.00M | - |
GBIO | Generation Bio | $5.90M | $4.09M |
IPSC | Century Therapeutics | $2.23M | $791.00K |
BCEL | Atreca | $770.00K | $80.00K |
LYEL | Lyell Immunopharma | $130.00K | $34.00K |
BDTX | Black Diamond Therapeutics | - | - |
NGM | NGM Biopharmaceuticals | - | $165.00K |
NKTX | Nkarta | - | - |
PASG | Passage Bio | - | - |
MLYS | Mineralys Therapeutics | - | - |
SANA | Sana Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |